The molecular basis for exceptional responses to ibrutinib in DLBCLs has been explained on cell lines and tumor biopsies by the formation of a multiprotein super-complex formed by MYD88, TLR9, and the BCR, whose presence differentiate ibrutinib responders from non-responders [32]. The gene discussed is MYD88; the disease is neoplasm.